Ernexa Therapeutics walks into its May 14 earnings event with one of the most charged short-selling setups in the micro-cap biotech universe.
The borrow market tells the clearest story. Cost to borrow has exploded to 894% APR — a record high for the stock and more than double where it was just a week ago, when it sat near 442%. That kind of borrow cost reflects acute demand for short exposure in a name where shares are genuinely hard to find. Availability has tightened to just 2.8% of estimated short interest, meaning fewer than three shares remain available for every hundred already borrowed. At that level, the lending pool is effectively exhausted.
Short interest is running at roughly 27% of the free float — extreme for any stock, but especially for a micro-cap with a market cap of around $8.4 million. That position has been volatile. It surged more than 150% over the past month as the stock itself tripled, then pulled back nearly a quarter in a single session on May 11. The short score has settled near 81 out of 100, deep into the high-conviction range, and has held there for the better part of the past week.
The price action adds important context. ERNA is up 201% over the past week and 146% over the past month, closing at $12.01. That move follows an announcement on May 11 that sent the stock up nearly 60% in a single day — the company dropped what appears to be a pipeline update alongside quarterly results, with reports of an 78% rally at points during the session. The stock is heading into tomorrow's print having already delivered one explosive session this week, with short sellers who built positions at lower levels now sitting on significant losses.
The ownership structure is tightly held. Charles Cherington, listed as a former director, controls roughly 23% of shares outstanding and added $2 million worth of stock in February 2026 at $0.50 per share — a bet made at a fraction of current levels. With float this thin and borrow this expensive, the mechanics of any further short covering are compressed: there are almost no shares available, costs are punishing, and the largest holder has no incentive to lend.
Tomorrow's print is therefore less a question of quarterly results and more a test of whether the catalyst that drove the May 11 move carries enough substance to hold the stock at these levels — or whether short sellers, paying nearly 900% to stay in the trade, find a reason to push back.
See the live data behind this article on ORTEX.
Open ERNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
